Factors influencing response to blinatumomab in relapsed/refractory ALL

Round-up of the latest research on lung cancer

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma

ASCO 2015: Latest developments in multiple myeloma

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs

Advanced DNA sequencing test used to match rare cancers

Developments in clinical trials and health information technology that will improve targeted therapies for patients

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis